Ironwood Pharmaceuticals to Host Q4 and Full Year 2025 Investor Call

The biotech company will provide an update on its gastrointestinal and rare disease therapies.

Published on Feb. 22, 2026

Got story updates? Submit your updates here. ›

Ironwood Pharmaceuticals, a biotechnology company focused on developing life-changing therapies for people with gastrointestinal and rare diseases, announced it will host its fourth quarter and full year 2025 investor update conference call and webcast on February 25, 2026.

Why it matters

As a leader in the development of treatments for conditions like irritable bowel syndrome and chronic constipation, Ironwood's quarterly and annual updates provide insights into the company's pipeline, commercial performance, and strategic direction - all of which are important for investors and the broader healthcare community.

The details

The investor call and webcast will take place at 8:30 a.m. Eastern Time on February 25, 2026. Participants can dial in using the provided conference ID and passcode. A replay of the call will be available for two weeks following the event.

  • The investor call and webcast will be held on Wednesday, February 25, 2026 at 8:30 a.m. Eastern Time.
  • The replay of the call will be available through Wednesday, March 11, 2026.

The players

Ironwood Pharmaceuticals

A biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases, including the marketed product LINZESS.

Got photos? Submit your photos here. ›

What’s next

Investors and analysts will be able to access the replay of the call and webcast on Ironwood's website in the days following the event.

The takeaway

Ironwood's quarterly and annual investor updates provide important insights into the company's progress in developing innovative treatments for underserved gastrointestinal and rare disease patients.